Hologic, Inc. $HOLX Shares Sold by Integral Health Asset Management LLC

Integral Health Asset Management LLC lessened its stake in Hologic, Inc. (NASDAQ:HOLX) by 20.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 100,000 shares of the medical equipment provider’s stock after selling 25,000 shares during the quarter. Integral Health Asset Management LLC’s holdings in Hologic were worth $6,749,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Invesco Ltd. lifted its position in shares of Hologic by 72.5% in the second quarter. Invesco Ltd. now owns 8,340,785 shares of the medical equipment provider’s stock valued at $543,486,000 after acquiring an additional 3,505,828 shares in the last quarter. Becker Capital Management Inc. increased its position in shares of Hologic by 20.0% during the third quarter. Becker Capital Management Inc. now owns 81,755 shares of the medical equipment provider’s stock worth $5,518,000 after purchasing an additional 13,610 shares in the last quarter. Illinois Municipal Retirement Fund increased its position in shares of Hologic by 20.4% during the third quarter. Illinois Municipal Retirement Fund now owns 172,294 shares of the medical equipment provider’s stock worth $11,628,000 after purchasing an additional 29,143 shares in the last quarter. Readystate Asset Management LP acquired a new position in Hologic in the 3rd quarter valued at $4,161,000. Finally, Natixis Advisors LLC raised its stake in Hologic by 23.4% in the 3rd quarter. Natixis Advisors LLC now owns 437,338 shares of the medical equipment provider’s stock valued at $29,516,000 after purchasing an additional 82,894 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. BNP Paribas Exane cut shares of Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 target price on the stock. in a research note on Friday, November 21st. Evercore cut shares of Hologic from an “outperform” rating to an “in-line” rating and reduced their target price for the company from $79.00 to $78.00 in a research report on Monday, January 5th. Argus downgraded shares of Hologic from a “buy” rating to a “hold” rating in a research note on Monday, January 12th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a research note on Wednesday, January 28th. Two investment analysts have rated the stock with a Buy rating and thirteen have given a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $78.42.

Hologic Trading Down 0.1%

HOLX opened at $75.12 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.32 and a current ratio of 4.04. The business’s 50-day simple moving average is $75.13 and its 200-day simple moving average is $72.64. The company has a market cap of $16.77 billion, a P/E ratio of 31.30, a PEG ratio of 2.24 and a beta of 0.73. Hologic, Inc. has a one year low of $51.90 and a one year high of $75.75.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Thursday, January 29th. The medical equipment provider reported $1.04 EPS for the quarter, missing the consensus estimate of $1.09 by ($0.05). Hologic had a return on equity of 19.58% and a net margin of 13.18%.The company had revenue of $1.05 billion for the quarter, compared to analyst estimates of $1.07 billion. During the same quarter in the prior year, the business earned $0.87 earnings per share. Hologic’s revenue was up 2.5% compared to the same quarter last year. As a group, equities research analysts expect that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Hologic Company Profile

Hologic, Inc (NASDAQ: HOLX) is a global medical technology company specializing in women’s health. Headquartered in Marlborough, Massachusetts, the company develops and manufactures diagnostic products, imaging systems and surgical solutions designed to detect, diagnose and treat diseases with a primary focus on breast and skeletal health, gynecological conditions and molecular diagnostics. Its product portfolio includes digital mammography systems, 3D mammography solutions, bone densitometry equipment and molecular assays for infectious disease and oncology applications.

Since its founding in 1985, Hologic has grown through both internal innovation and strategic acquisitions.